Total Payments
$684,932
2024 Payments
$66,198
Companies
51
Transactions
951
Medicare Patients
21,998
Medicare Billing
$2.7M
Payment Breakdown by Category
Other$395,726 (57.8%)
Consulting$186,617 (27.2%)
Travel$71,757 (10.5%)
Food & Beverage$25,718 (3.8%)
Research$4,800 (0.7%)
Education$314.16 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $346,721 | 132 | 50.6% |
| Consulting Fee | $186,617 | 77 | 27.2% |
| Travel and Lodging | $71,757 | 164 | 10.5% |
| Honoraria | $46,005 | 32 | 6.7% |
| Food and Beverage | $25,718 | 521 | 3.8% |
| Unspecified | $4,800 | 13 | 0.7% |
| Compensation for serving as faculty or as a speaker for an accredited or certified continuing education program | $3,000 | 1 | 0.4% |
| Education | $314.16 | 11 | 0.0% |
Payments by Type
General
$680,132
938 transactions
Research
$4,800
4 transactions
Ownership
$0
9 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Janssen Biotech, Inc. | $139,326 | 189 | $0 (2024) |
| Astellas Pharma US Inc | $119,171 | 135 | $0 (2024) |
| Janssen Scientific Affairs, LLC | $67,972 | 50 | $0 (2024) |
| Myovant Sciences Inc. | $67,589 | 41 | $0 (2022) |
| Bayer Healthcare Pharmaceuticals Inc. | $63,161 | 79 | $0 (2024) |
| SN Holdings, LLC | $39,023 | 61 | $0 (2024) |
| UroGPO LLC | $32,459 | 37 | $0 (2020) |
| PFIZER INC. | $25,918 | 74 | $0 (2024) |
| Dendreon Pharmaceuticals LLC | $19,908 | 26 | $0 (2024) |
| Sumitomo Pharma America, Inc. | $18,774 | 27 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $66,198 | 91 | Janssen Biotech, Inc. ($25,319) |
| 2023 | $86,831 | 106 | Bayer Healthcare Pharmaceuticals Inc. ($21,492) |
| 2022 | $100,767 | 135 | Myovant Sciences Inc. ($30,244) |
| 2021 | $92,138 | 77 | Myovant Sciences Inc. ($37,345) |
| 2020 | $61,796 | 56 | Astellas Pharma US Inc ($19,738) |
| 2019 | $89,343 | 127 | Janssen Biotech, Inc. ($36,060) |
| 2018 | $105,344 | 181 | Janssen Scientific Affairs, LLC ($43,689) |
| 2017 | $82,517 | 178 | Astellas Pharma US Inc ($34,246) |
All Payment Transactions
951 individual payment records from CMS Open Payments — Page 1 of 39
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/10/2024 | Novartis Pharmaceuticals Corporation | PLUVICTO (Drug) | Food and Beverage | In-kind items and services | $29.05 | General |
| Category: Oncology | ||||||
| 11/27/2024 | Janssen Biotech, Inc. | ERLEADA (Drug), AKEEGA | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,125.00 | General |
| Category: Oncology | ||||||
| 11/22/2024 | UROGEN PHARMA, INC. | — | Consulting Fee | Cash or cash equivalent | $1,562.50 | General |
| 11/21/2024 | Janssen Biotech, Inc. | ERLEADA (Drug), AKEEGA | Travel and Lodging | In-kind items and services | $1,168.70 | General |
| Category: Oncology | ||||||
| 11/20/2024 | Janssen Biotech, Inc. | ERLEADA (Drug), AKEEGA | Food and Beverage | In-kind items and services | $106.05 | General |
| Category: Oncology | ||||||
| 11/14/2024 | Astellas Pharma US Inc | Xtandi (Drug) | Food and Beverage | In-kind items and services | $164.57 | General |
| Category: Oncology | ||||||
| 11/14/2024 | Janssen Scientific Affairs, LLC | ERLEADA (Drug) | Food and Beverage | In-kind items and services | $35.05 | General |
| Category: Oncology | ||||||
| 11/07/2024 | PFIZER INC. | XTANDI (Drug), ORGOVYX, TALZENNA | Food and Beverage | In-kind items and services | $18.68 | General |
| Category: ONCOLOGY | ||||||
| 11/06/2024 | PFIZER INC. | XTANDI (Drug) | — | In-kind items and services | $330.00 | Research |
| Study: XTANDI CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 11/05/2024 | Sumitomo Pharma America, Inc. | ORGOVYX (Drug) | Food and Beverage | In-kind items and services | $25.39 | General |
| Category: HORMONE THERAPY | ||||||
| 11/01/2024 | Janssen Biotech, Inc. | ERLEADA (Drug), AKEEGA | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $550.00 | General |
| Category: Oncology | ||||||
| 10/25/2024 | Janssen Biotech, Inc. | ERLEADA (Drug), AKEEGA | Food and Beverage | In-kind items and services | $23.41 | General |
| Category: Oncology | ||||||
| 10/22/2024 | Novartis Pharmaceuticals Corporation | PLUVICTO (Drug) | Food and Beverage | In-kind items and services | $14.63 | General |
| Category: Oncology | ||||||
| 10/17/2024 | Dendreon Pharmaceuticals LLC | PROVENGE (Drug) | Food and Beverage | In-kind items and services | $33.68 | General |
| Category: CELLULAR BIOLOGIC TREATMENT FOR PROSTATE CANCER | ||||||
| 10/14/2024 | Janssen Biotech, Inc. | ERLEADA (Drug) | Food and Beverage | In-kind items and services | $142.31 | General |
| Category: Oncology | ||||||
| 10/11/2024 | Janssen Biotech, Inc. | ERLEADA (Drug), AKEEGA | Travel and Lodging | In-kind items and services | $5.50 | General |
| Category: Oncology | ||||||
| 10/10/2024 | Novartis Pharmaceuticals Corporation | — | Consulting Fee | Cash or cash equivalent | $2,100.00 | General |
| 10/10/2024 | Janssen Biotech, Inc. | ERLEADA (Drug), AKEEGA | Travel and Lodging | In-kind items and services | $5.50 | General |
| Category: Oncology | ||||||
| 10/09/2024 | Janssen Biotech, Inc. | ERLEADA (Drug), AKEEGA | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,575.00 | General |
| Category: Oncology | ||||||
| 10/09/2024 | UROGEN PHARMA, INC. | JELMYTO (Drug) | Food and Beverage | In-kind items and services | $15.27 | General |
| Category: UROTHELIAL CANCER | ||||||
| 10/08/2024 | Myriad Genetic Laboratories, Inc. | PROLARIS (Device) | Food and Beverage | In-kind items and services | $33.66 | General |
| Category: ONCOLOGY | ||||||
| 09/21/2024 | Telix Pharmaceuticals | ILLUCCIX (Drug) | Food and Beverage | In-kind items and services | $105.09 | General |
| Category: PROSTATE CANCER DIAGNOSIS | ||||||
| 09/21/2024 | Telix Pharmaceuticals | ILLUCCIX (Drug) | Food and Beverage | In-kind items and services | $102.41 | General |
| Category: PROSTATE CANCER DIAGNOSIS | ||||||
| 09/21/2024 | Telix Pharmaceuticals | ILLUCCIX (Drug) | Food and Beverage | In-kind items and services | $72.58 | General |
| Category: PROSTATE CANCER DIAGNOSIS | ||||||
| 09/20/2024 | Telix Pharmaceuticals | ILLUCCIX (Drug) | Food and Beverage | In-kind items and services | $169.42 | General |
| Category: PROSTATE CANCER DIAGNOSIS | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| RELUGOLIX CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $3,200 | 1 |
| SASANLIMAB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $940.00 | 1 |
| RN888 CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $330.00 | 1 |
| XTANDI CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $330.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 42 | 5,207 | 19,766 | $1.5M | $533,270 |
| 2022 | 46 | 5,745 | 37,174 | $2.0M | $770,107 |
| 2021 | 43 | 5,606 | 38,552 | $2.0M | $720,223 |
| 2020 | 43 | 5,440 | 42,175 | $2.1M | $721,434 |
Total Patients
21,998
Total Services
137,667
Medicare Billing
$2.7M
Procedure Codes
174
All Medicare Procedures & Services
174 procedure records from CMS Medicare Utilization — Page 1 of 7
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 44 | 10,320 | $319,920 | $189,739 | 59.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 661 | 1,062 | $228,330 | $92,096 | 40.3% |
| 87798 | Detection test by nucleic acid for organism, amplified probe technique | Office | 2023 | 112 | 1,608 | $125,424 | $55,296 | 44.1% |
| 99490 | Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2023 | 171 | 787 | $62,886 | $31,720 | 50.4% |
| 52000 | Diagnostic exam of bladder and urethra using an endoscope | Office | 2023 | 107 | 124 | $60,760 | $22,106 | 36.4% |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | Office | 2023 | 27 | 150 | $105,000 | $19,609 | 18.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 267 | 290 | $43,500 | $16,570 | 38.1% |
| 84153 | Psa (prostate specific antigen) measurement, total | Office | 2023 | 592 | 864 | $95,040 | $15,569 | 16.4% |
| 84403 | Testosterone (hormone) level, total | Office | 2023 | 260 | 501 | $75,150 | $12,670 | 16.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 105 | 105 | $32,865 | $12,165 | 37.0% |
| 51798 | Ultrasound measurement of bladder capacity after voiding | Office | 2023 | 678 | 900 | $85,500 | $6,151 | 7.2% |
| 74178 | Ct scan of abdomen and pelvis before and after contrast | Office | 2023 | 25 | 25 | $17,500 | $5,736 | 32.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 36 | 38 | $11,020 | $4,839 | 43.9% |
| 52356 | Crushing of stone of ureter with insertion of stent using an endoscope | Facility | 2023 | 15 | 15 | $30,000 | $4,675 | 15.6% |
| 87481 | Detection test for candida species (yeast), amplified probe technique | Office | 2023 | 112 | 133 | $10,374 | $4,574 | 44.1% |
| 87640 | Detection test by nucleic acid for staphylococcus aureus (bacteria), amplified probe technique | Office | 2023 | 112 | 133 | $10,374 | $4,574 | 44.1% |
| 87653 | Detection test by nucleic acid for strep (streptococcus, group b), amplified probe technique | Office | 2023 | 111 | 132 | $10,296 | $4,539 | 44.1% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 57 | 57 | $11,970 | $4,473 | 37.4% |
| 81001 | Manual urinalysis test with examination using microscope, automated | Office | 2023 | 827 | 1,260 | $18,900 | $3,885 | 20.6% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 32 | 32 | $8,800 | $3,106 | 35.3% |
| 96402 | Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 44 | 91 | $6,825 | $2,079 | 30.5% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 27 | 56 | $5,040 | $1,997 | 39.6% |
| G0416 | Surgical pathology, gross and microscopic examinations, for prostate needle biopsy, any method | Office | 2023 | 15 | 15 | $10,270 | $1,874 | 18.2% |
| 80048 | Blood test, basic group of blood chemicals (calcium, total) | Office | 2023 | 120 | 198 | $8,910 | $1,641 | 18.4% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 112 | 152 | $1,520 | $1,268 | 83.4% |
About Dr. Daniel Saltzstein, MD
Dr. Daniel Saltzstein, MD is a Surgery healthcare provider based in San Antonio, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/17/2006. The National Provider Identifier (NPI) number assigned to this provider is 1922088947.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Daniel Saltzstein, MD has received a total of $684,932 in payments from pharmaceutical and medical device companies, with $66,198 received in 2024. These payments were reported across 951 transactions from 51 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($346,721).
As a Medicare-enrolled provider, Saltzstein has provided services to 21,998 Medicare beneficiaries, totaling 137,667 services with total Medicare billing of $2.7M. Data is available for 4 years (2020–2023), covering 174 distinct procedure/service records.
Ad
Practice Information
- Specialty Surgery
- Other Specialties Urology
- Location San Antonio, TX
- Active Since 01/17/2006
- Last Updated 10/08/2018
- Taxonomy Code 208600000X
- Entity Type Individual
- NPI Number 1922088947
Products in Payments
- ORGOVYX (Drug) $94,285
- Erleada (Drug) $90,502
- ERLEADA (Drug) $89,081
- XTANDI (Drug) $84,702
- Nubeqa (Drug) $44,659
- Xtandi (Drug) $34,439
- PROVENGE (Drug) $19,921
- DARZALEX (Biological) $16,656
- Xofigo (Drug) $16,427
- PYLARIFY (Drug) $15,161
- PLUVICTO (Drug) $9,534
- LYNPARZA (Drug) $5,110
- Bavencio (Biological) $5,086
- YONSA (Drug) $4,324
- ELIGARD (Drug) $4,278
- FOUNDATIONACT (Device) $3,762
- RUBRACA (Drug) $3,133
- JELMYTO (Drug) $2,482
- ADSTILADRIN (Biological) $2,205
- ZYTIGA (Drug) $2,188
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Surgery Doctors in San Antonio
Joseph Karam, M.d, M.D
Surgery — Payments: $335,925
Surgery $335,925
Dr. William Lewis, M.d, M.D
Surgery — Payments: $315,348
Surgery $315,348
Dr. John Metersky, M.d, M.D
Surgery — Payments: $296,633
Surgery $296,633
Dr. Richard Peterson, M.d., M.p.h, M.D., M.P.H
Surgery — Payments: $292,402
Surgery $292,402
John Pilcher, Md, MD
Surgery — Payments: $222,583
Surgery $222,583
Dr. Christopher De Jesus, M.d, M.D
Surgery — Payments: $175,855
Surgery $175,855